Keywords

antidepressant medication, brexanolone, postpartum depression, PPD

 

Authors

  1. Burval, Jessica BSPS
  2. Kerns, Rachel PharmD
  3. Reed, Kim RN, OCN

Abstract

Abstract: The FDA has approved brexanolone specifically for treatment of adults with postpartum depression (PPD). Administered I.V., it can relieve severe signs and symptoms of PPD within days rather than weeks. This article discusses the benefits and risks of brexanolone as a treatment for PPD, including nursing considerations and patient teaching.